Patents by Inventor Markus Hörer
Markus Hörer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230323387Abstract: The present invention relates to helper plasmids and two-plasmid systems for producing recombinant AAV (rAAV) vectors. The invention further relates to methods of using, or uses of the helper plasmids and two-plasmid systems of the invention. The present invention also relates to a helper plasmid which does not comprise a cap gene encoding a functional set of Cap proteins and which does comprise at least one rep gene and at least one helper virus gene.Type: ApplicationFiled: October 12, 2021Publication date: October 12, 2023Inventors: Florian Sonntag, Andreas Schulze, Bettina Finkbeiner, Markus Hörer
-
Publication number: 20220162642Abstract: The present invention relates to two-plasmid systems, helper plasmids, and/or vector plasmids for producing recombinant AAV (rAAV) vectors. The invention further relates to methods using, or uses of, the two-plasmid systems, helper plasmids and/or vector plasmids of the invention.Type: ApplicationFiled: April 14, 2020Publication date: May 26, 2022Inventors: Markus HÖRER, Florian SONNTAG, Renée KOBER
-
Patent number: 11267847Abstract: The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” (AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for the preparation of the parvoviral particle and methods of producing parvoviral particles essentially consisting of VP3 by providing in addition to the coding sequence of the parvoviral structural protein VP3 a sequence fragment Z/a nucleic acid encoding AAP in the cell and expressing VP3 and fragment Z under control of a rep-independent promoter. Furthermore, the present invention relates to parvoviral particles essentially consisting of VP3 and/or obtainable by the above method as well as expression cassettes comprising (i) a heterologous promoter and (ii) VP3 coding sequence and/or fragment Z.Type: GrantFiled: May 17, 2019Date of Patent: March 8, 2022Assignees: Medigene AG, Deutsches KrebsforschungszentrumInventors: Florian Sonntag, Juergen Kleinschmidt, Markus Hoerer, Kerstin Pino Tossi
-
Patent number: 10822378Abstract: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid or multimeric structure as well as methods and uses involving the protein, nucleic acid or multimeric structure.Type: GrantFiled: April 10, 2017Date of Patent: November 3, 2020Assignees: Medigene AG, Ludwig-Maximilians-Universitaet, Universitaet zu KoelnInventors: Kerstin Lux, Hildegard Buening, John Nieland, Jorge Boucas, Mirko Ritter, Markus Hoerer, Luca Perabo, Michael Hallek
-
Publication number: 20200239859Abstract: The invention generally concerns the production of defective Adenovirus helper viruses for producing a recombinant adeno-associated virus (rAAV), wherein the Adenovirus helper virus contains at least one mutation selected from (a) an inactivating mutation in the transcription unit coding for the L4-100K protein; (b) an inactivating mutation in the transcription unit coding for the L1-52/55K protein; (c) an inactivating mutation in the transcription unit coding for the preterminal protein (pTP); (d) a mutation in the L4-100K protein in order to render it temperature-sensitive (ts); (e) a mutation in the hexon protein in order to render it temperature-sensitive (ts); and/or (f) a mutation in the L4-00K protein and a mutation in the hexon protein in order to render it temperature-sensitive (ts).Type: ApplicationFiled: October 12, 2018Publication date: July 30, 2020Inventors: Markus HÖRER, Stefan KOCHANEK, Caroline HAUSER, Alexandra KRÜGER-HAAG
-
Publication number: 20200191788Abstract: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimerc structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.Type: ApplicationFiled: July 26, 2019Publication date: June 18, 2020Inventors: Hildegard BUENING, John NIELAND, Luca PERABO, Daniela KUEHN, Kerstin PINOTOSSI, Michael HALLEK, Markus HOERER, Mirko RITTER
-
Publication number: 20200087352Abstract: The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” (AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for the preparation of the parvoviral particle and methods of producing parvoviral particles essentially consisting of VP3 by providing in addition to the coding sequence of the parvoviral structural protein VP3 a sequence fragment Z/a nucleic acid encoding AAP in the cell and expressing VP3 and fragment Z under control of a rep-independent promoter. Furthermore, the present invention relates to parvoviral particles essentially consisting of VP3 and/or obtainable by the above method as well as expression cassettes comprising (i) a heterologous promoter and (ii) VP3 coding sequence and/or fragment Z.Type: ApplicationFiled: May 17, 2019Publication date: March 19, 2020Inventors: Florian SONNTAG, Juergen KLEINSCHMIDT, Markus HOERER, Kerstin PINO TOSSI
-
Patent number: 10408834Abstract: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.Type: GrantFiled: November 2, 2015Date of Patent: September 10, 2019Assignees: Medigene AG, Ludwig-Maximilians-Universitaet, Universitaet zu KoelnInventors: Hildegard Buening, John Nieland, Luca Perabo, Daniela Kuehn, Kerstin Pinotossi, Michael Hallek, Markus Hoerer, Mirko Ritter
-
Patent number: 10344057Abstract: The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” (AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for the preparation of the parvoviral particle and methods of producing parvoviral particles essentially consisting of VP3 by providing in addition to the coding sequence of the parvoviral structural protein VP3 a sequence fragment Z/a nucleic acid encoding AAP in the cell and expressing VP3 and fragment Z under control of a rep-independent promoter. Furthermore, the present invention relates to parvoviral particles essentially consisting of VP3 and/oror obtainable by the above method as well as expression cassettes comprising (i) a heterologous promoter and (ii) VP3 coding sequence and/oror fragment Z.Type: GrantFiled: September 12, 2016Date of Patent: July 9, 2019Assignees: Deutsches Krebsforschungszentrum, Medigene AGInventors: Florian Sonntag, Juergen Kleinschmidt, Markus Hoerer, Kerstin Pino Tossi
-
Publication number: 20180066024Abstract: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid or multimeric structure as well as methods and uses involving the protein, nucleic acid or multimeric structure.Type: ApplicationFiled: April 10, 2017Publication date: March 8, 2018Applicants: Medigene AG, Ludwig-Maximilians-Universitaet, Universitaet zu KoelnInventors: Kerstin LUX, Hildegard BUENING, John NIELAND, Jorge BOUCAS, Mirko RITTER, Markus HOERER, Luca PERABO, Michael HALLEK
-
Publication number: 20170226160Abstract: The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” S(AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for the preparation of the parvoviral particle and methods of producing parvoviral particles essentially consisting of VP3 by providing in addition to the coding sequence of the parvoviral structural protein VP3 a sequence fragment Z/a nucleic acid encoding AAP in the cell and expressing VP3 and fragment Z under control of a rep-independent promoter. Furthermore, the present invention relates to parvoviral particles essentially consisting of VP3 and/or obtainable by the above method as well as expression cassettes comprising (i) a heterologous promoter and (ii) VP3 coding sequence and/or fragment Z.Type: ApplicationFiled: September 12, 2016Publication date: August 10, 2017Inventors: Florian SONNTAG, Juergen KLEINSCHMIDT, Markus HOERER, Kerstin LUX
-
Patent number: 9624274Abstract: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus, or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid, or multimeric structure as well as methods and uses involving the protein, nucleic acid, or multimeric structure.Type: GrantFiled: October 11, 2012Date of Patent: April 18, 2017Assignees: Medigene AG, Ludwig-Maximilians-Universitaet, Universitaet zu KoelnInventors: Kerstin Lux, Hildegard Buening, John Nieland, Jorge Boucas, Mirko Ritter, Markus Hoerer, Luca Perabo, Michael Hallek
-
Patent number: 9464119Abstract: The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” (AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for the preparation of the parvoviral particle and methods of producing parvoviral particles essentially consisting of VP3. Furthermore, the invention relates to parvoviral particles essentially consisting of VP3 and/or obtainable by the above method as well as expression cassettes comprising (i) a heterologous promoter and (ii) VP3 coding sequence and/or fragment Z. The invention further relates to a medicament, particularly a vaccine, comprising the parvoviral particles or expression cassettes and their use.Type: GrantFiled: March 4, 2010Date of Patent: October 11, 2016Assignees: Deutsches Krebsforschungszentrum, Medigene AGInventors: Florian Sonntag, Juergen Kleinschmidt, Markus Hoerer, Kerstin Lux
-
Publication number: 20160153992Abstract: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.Type: ApplicationFiled: November 2, 2015Publication date: June 2, 2016Inventors: Hildegard BUENING, John NIELAND, Luca PERABO, Daniela KUEHN, Kerstin LUX, Michael HALLEK, Markus HOERER, Mirko RITTER
-
Publication number: 20130288921Abstract: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.Type: ApplicationFiled: July 9, 2013Publication date: October 31, 2013Inventors: Hildegard BUENING, John Nieland, Luca Perabo, Daniela Kuehn, Kerstin Lux, Michael Hallek, Markus Hoerer, Mirko Ritter
-
Publication number: 20120135022Abstract: The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” (AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for the preparation of the parvoviral particle and methods of producing parvoviral particles essentially consisting of VP3 by providing in addition to the coding sequence of the parvoviral structural protein VP3 a sequence fragment Z/a nucleic acid encoding AAP in the cell and expressing VP3 and fragment Z under control of a rep-independent promoter. Furthermore, the present invention relates to parvoviral particles essentially consisting of VP3 and/or obtainable by the above method as well as expression cassettes comprising (i) a heterologous promoter and (ii) VP3 coding sequence and/or fragment Z.Type: ApplicationFiled: March 4, 2010Publication date: May 31, 2012Applicants: MediGene AG, Deutsches KrebsforschungszentrumInventors: Florian Sonntag, Juergen Kleinschmidt, Markus Hoerer, Kerstin Lux
-
Publication number: 20100297177Abstract: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.Type: ApplicationFiled: June 2, 2008Publication date: November 25, 2010Applicants: Ludwig-Maximillians-Universitaet, Klinikum der Universitaet zu KoelnInventors: Hildegard Buening, John Nieland, Luca Perabo, Daniela Kuehn, Kerstin Lux, Michael Hallek, Markus Hoerer, Mirko Ritter
-
Publication number: 20100203083Abstract: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid or multimeric structure as well as methods and uses involving the protein, nucleic acid or multimeric structure.Type: ApplicationFiled: June 2, 2008Publication date: August 12, 2010Inventors: Kerstin Lux, Hildegard Buening, Luca Perabo, John Nieland, Jorge Boucas, Michael Hallek, Mirko Ritter, Markus Hoerer
-
Patent number: 6846665Abstract: The present invention relates to a method for producing a recombinant adeno-associated virus (rAAV), in which at different times a helper construct and also a vector construct are introduced into a suitable cell, and preferably the helper construct does not comprise, in particular with the exception of the AAV promoters, any nucleic acid sequences to which at least a Rep protein can essentially specifically bind and preferably the vector construct comprises ITR sequences in flop orientation. The recombinant adeno-associated viruses produced according to the method of the invention are suitable in particular for producing a tumor cell into which additionally nucleic acids coding for GM-CSF and B7.2 has been introduced, which in turn can be used in the form of a medicament for the treatment of cancers.Type: GrantFiled: February 10, 2000Date of Patent: January 25, 2005Assignee: MediGene AktiengesellschaftInventors: Markus Hörer, Michael Hallek
-
Patent number: 6838272Abstract: The invention relates to a process for separating viruses of different sizes, with the virus-containing solution preferably being filtered through one or more filter membranes.Type: GrantFiled: September 26, 2002Date of Patent: January 4, 2005Assignee: Switch Biotech AGInventors: Christoph Bogedain, Gerhard Maass, Markus Hörer